Amarin Co. plc (NASDAQ:AMRN) Short Interest Update

Amarin Co. plc (NASDAQ:AMRN - Get Free Report) saw a large decrease in short interest in April. As of April 15th, there was short interest totalling 15,840,000 shares, a decrease of 12.1% from the March 31st total of 18,020,000 shares. Based on an average daily volume of 1,680,000 shares, the days-to-cover ratio is currently 9.4 days.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reissued an "overweight" rating on shares of Amarin in a research report on Friday, January 12th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat, Amarin currently has an average rating of "Hold" and an average price target of $1.08.

Hedge Funds Weigh In On Amarin

A number of large investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. boosted its holdings in Amarin by 351.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 44,599 shares of the biopharmaceutical company's stock worth $39,000 after purchasing an additional 34,725 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Amarin by 16.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 122,498 shares of the biopharmaceutical company's stock valued at $113,000 after acquiring an additional 17,613 shares in the last quarter. SVB Wealth LLC grew its stake in shares of Amarin by 100.0% in the 4th quarter. SVB Wealth LLC now owns 60,000 shares of the biopharmaceutical company's stock worth $52,000 after buying an additional 30,000 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its stake in Amarin by 35.7% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 649,152 shares of the biopharmaceutical company's stock worth $597,000 after buying an additional 170,670 shares during the period. Finally, Tokio Marine Asset Management Co. Ltd. raised its holdings in shares of Amarin by 18.9% in the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 129,200 shares of the biopharmaceutical company's stock worth $119,000 after buying an additional 20,500 shares during the period. Hedge funds and other institutional investors own 22.25% of the company's stock.

Amarin Trading Up 1.7 %

Shares of AMRN traded up $0.01 on Friday, reaching $0.87. The company's stock had a trading volume of 490,768 shares, compared to its average volume of 1,207,184. Amarin has a twelve month low of $0.65 and a twelve month high of $1.49. The stock has a market capitalization of $359.30 million, a PE ratio of -6.25 and a beta of 1.98. The firm has a fifty day moving average of $0.97 and a 200-day moving average of $0.93.

Amarin (NASDAQ:AMRN - Get Free Report) last issued its quarterly earnings results on Thursday, February 29th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.04. The company had revenue of $74.71 million during the quarter, compared to analyst estimates of $72.46 million. Amarin had a negative net margin of 19.26% and a negative return on equity of 10.47%. As a group, equities analysts anticipate that Amarin will post -0.14 EPS for the current fiscal year.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.